Drugs News and Research

RSS

Gay young men in serious relationships more likely to have unprotected sex

Gay young men in serious relationships are six times more likely to have unprotected sex than those who hook up with casual partners, according to new Northwestern Medicine research.

2 Jun 2011

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Somnus Therapeutics, Inc., a private specialty pharmaceutical company, has completed a Phase 2 dose-ranging study of SKP-1041, a modified-release formulation of zaleplon.

2 Jun 2011

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.

2 Jun 2011

Viewpoints: More on Medicare's 'hard choices'; elderly and anti-psychotics; Calif. insurance rate hikes

Unless we make hard decisions now, in less than a decade every dollar of federal revenue will go to covering the costs of Medicare, Social Security and interest payments on our debt. ... I admire Congressman Paul Ryan's honest attempt to save Medicare.

2 Jun 2011

Scientists discover key biological mechanism underpinning transition to alcohol dependence

A team of Scripps Research Institute scientists has found a key biological mechanism underpinning the transition to alcohol dependence. This finding opens the door to the development of drugs to manage excessive alcohol consumption.

1 Jun 2011

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

1 Jun 2011

Repro-Med Systems receives FDA marketing approval for new subcutaneous needle sets

Repro-Med Systems, Inc., announced today that it has received approval from the Food and Drug Administration to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo RMS Subcutaneous Needle Sets.

1 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

Shield raises EUR8.2M through Series A financing

Shield Therapeutics, the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has successfully raised EUR8.2m from Inventages Venture Capital (Inventages) in its first institutional financing round.

1 Jun 2011

Natural killer cells promote induction of dry eye disease: New discovery

If you are one of the millions of people around the world who struggle with dry eye disease, good news is on the way. A new research discovery published in the Journal of Leukocyte Biology offers hope for new drugs that treat the cellular cause of the disease rather than its symptoms.

1 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

Ontario's doctors urge people to quit smoking on ‘World No Tobacco Day’

Today is World No Tobacco Day and Ontario's doctors are taking the opportunity to remind people about the dangers of smoking and are urging smokers to talk to their doctor about how they can quit for good.

1 Jun 2011

Wall Street Journal reports on U.N. AIDS declaration negotiations prior to high level meeting

The Wall Street Journal reports on negotiations surrounding a U.N. declaration to be discussed at the High Level Meeting on AIDS scheduled for June 8-10 in New York.

1 Jun 2011

At the 30 year mark, AIDS epidemic still poses challenges

Thirty years after America started battling HIV/AIDS, deaths linked to the virus have plummeted. New HIV cases are down by three-quarters. Life expectancy has more than tripled. Many HIV-positive people lead active lives, often on a single pill a day. But there's a darker side: More than 1.2 million Americans still are living with HIV/AIDS, and 40,000 new infections and 16,000 deaths are expected this year.

1 Jun 2011

New York Times examines 30 years of AIDS

The New York Times looks at the evolution of the battle against AIDS since the first federal announcement of the disease 30 years ago this week. "The epidemic has brought a new focus on the power of epidemiology to identify a disease's transmission patterns long before discovery of its cause.

1 Jun 2011

Women with ovarian cancer could benefit from new targeted testing

Women with ovarian cancer could be helped by a new test that identifies the specific type of tumour they have, a conference will hear this week.

1 Jun 2011

POWER study examines impact of HIV infection on Ontario women

Despite significant clinical advances in HIV care, an estimated 25 per cent of new HIV infections in Ontario from 2006 to 2008 were among women, according to a health study by researchers from the Institute for Clinical Evaluative Sciences and St. Michael's Hospital.

1 Jun 2011

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report.

1 Jun 2011

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis.

1 Jun 2011

Type II diabetes drug may slow or stop breast cancer tumor metastasis

A protein activated by certain drugs already approved for treating Type II diabetes may slow or stop the spread of breast tumors.

1 Jun 2011

Drugs News and Research

Gay young men in serious relationships more likely to have unprotected sex

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

Viewpoints: More on Medicare's 'hard choices'; elderly and anti-psychotics; Calif. insurance rate hikes

Scientists discover key biological mechanism underpinning transition to alcohol dependence

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Repro-Med Systems receives FDA marketing approval for new subcutaneous needle sets

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Shield raises EUR8.2M through Series A financing

Natural killer cells promote induction of dry eye disease: New discovery

Lymphoma vaccine extends disease-free survival by 14 months

Ontario's doctors urge people to quit smoking on ‘World No Tobacco Day’

Wall Street Journal reports on U.N. AIDS declaration negotiations prior to high level meeting

At the 30 year mark, AIDS epidemic still poses challenges

New York Times examines 30 years of AIDS

Women with ovarian cancer could benefit from new targeted testing

POWER study examines impact of HIV infection on Ontario women

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

Type II diabetes drug may slow or stop breast cancer tumor metastasis

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News